$29.63
+0.90 (+3.11%)
Open$28.74
Previous Close$28.74
Day High$29.92
Day Low$28.40
52W High$31.49
52W Low$16.00
Volume—
Avg Volume1.36M
Market Cap2.07B
P/E Ratio—
EPS$-2.01
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-39.7% upside
Current
$29.63
$29.63
Target
$17.86
$17.86
$12.55
$17.86 avg
$20.90
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 98.55M | 155.02M | 182.20M |
| Net Income | -75,448,334 | -106,816,895 | 28.41M |
| Profit Margin | -76.6% | -72.7% | 15.6% |
| EBITDA | -82,657,264 | -123,524,305 | 52.86M |
| Free Cash Flow | — | — | 21.80M |
| Rev Growth | -36.4% | -36.4% | +8.1% |
| Debt/Equity | — | — | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |